drugset
drugset / Trial / NCT02413255

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers

NCT02413255 ↗

Phase 1 Completed 120 enrolled Takeda
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ascending single- and multiple-doses of TAK-020 in healthy participants.

Timeline

Start
2015-03-18
Primary completion
2017-05-04
Completion
2017-05-04

Drugs

EvaluationDrugModalityDoseRoute
Subject TAK-020 Small molecule 0.1 mg Oral
Subject TAK-020 Small molecule 0.5 mg Oral
Subject TAK-020 Small molecule 2.5 mg Oral
Subject TAK-020 Small molecule 3.75 mg Oral
Subject TAK-020 Small molecule 4.4 mg Oral
Subject TAK-020 Small molecule 5.75 mg Oral
Subject TAK-020 Small molecule 8.8 mg Oral
Subject TAK-020 Small molecule 13 mg Oral
Subject TAK-020 Small molecule 17.5 mg Oral
Subject TAK-020 Small molecule 25 mg Oral
Subject TAK-020 Small molecule 35 mg Oral
Subject TAK-020 Small molecule 45 mg Oral
Subject TAK-020 Small molecule 60 mg Oral
Subject TAK-020 Small molecule 70 mg Oral
Subject TAK-020 Small molecule 105 mg Oral

Indications

No indication recorded.